Immune Checkpoint Inhibitors: all 7,569 studies that test it

Page 44 of 76. Open to participants first (2,567), then studies with results posted, then the rest; newest registration first within each.

• Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerSuspendedNCT06616623Phase 1
• PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerActive, not recruitingNCT06616532Phase 3
• BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular CarcinomaWithdrawnNCT06608940Phase 1/2
• Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06608927Phase 3
• Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast CancerCompletedNCT06604858Phase 2
• Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)WithdrawnNCT06603818Phase 2
• AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerActive, not recruitingNCT06591520Phase 3
• A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal CancerActive, not recruitingNCT06584435Phase 2
• Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT06580054Phase 2
• Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1Active, not recruitingNCT06579196Phase 1/2
• Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal CancerWithdrawnNCT06575725Phase 2
• Perioperative Immunotherapy for NSCLC (ECTOP-1030)WithdrawnNCT06572722Phase 2
• Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid TumorsActive, not recruitingNCT06571422Phase 1
• Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin CancerSuspendedNCT06568172Phase 3
• Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaActive, not recruitingNCT06566391Phase 2
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesActive, not recruitingNCT06564844Phase 3
• LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06558799Phase 2
• Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomasActive, not recruitingNCT06557889Phase 2
• A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLActive, not recruitingNCT06547528Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma PatientsActive, not recruitingNCT06540391Phase 1
• Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerWithdrawnNCT06528210Phase 2
• Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelActive, not recruitingNCT06523621Phase 2
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingNCT06521567Phase 1/2
• SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARCStatus unknownNCT06516445Phase 2
• Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical CancerActive, not recruitingNCT06511726Phase 2
• Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal CancerActive, not recruitingNCT06507371Phase 3
• A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)Active, not recruitingNCT06504394Phase 2
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain MetastasisCompletedNCT06501378Phase 2
• A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic CancerWithdrawnNCT06498518Phase 2
• Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous CarcinomaCompletedNCT06494189Phase 1
• Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal CancerCompletedNCT06493240Phase 2
• Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell LymphomaActive, not recruitingNCT06492629Phase 2
• A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Phase 1
• A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLCCompletedNCT06478043Phase 2
• Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLCActive, not recruitingNCT06477523Phase 1/2
• A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingNCT06472076Phase 3
• A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)CompletedNCT06470763Phase 1/2
• SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT06465563Phase 2
• Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid TumorsActive, not recruitingNCT06462222Phase 1/2
• Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyActive, not recruitingNCT06449222Phase 2
• Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyActive, not recruitingNCT06449209Phase 2
• Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLCActive, not recruitingNCT06448910Phase 2
• Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive, not recruitingNCT06448754Phase 2
• Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06447636Phase 2
• Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid CarcinomaCompletedNCT06446570Phase 2
• Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11CompletedNCT06440187Phase 2
• Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal CancerCompletedNCT06428487Phase 2
• Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical CancerActive, not recruitingNCT06419673Phase 2
• PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Phase 3
• Toripalimab for High-risk Locally Advanced Cervical CancerActive, not recruitingNCT06416696Phase 2
• Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer PatientsWithdrawnNCT06416436Phase 1
• TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile CancerCompletedNCT06415318Phase 2
• PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSCompletedNCT06413095Early Phase 1
• A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerWithdrawnNCT06410534Phase 2
• Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06405230Phase 1/2
• Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular CarcinomaSuspendedNCT06405061Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionStatus unknownNCT06396585Phase 2
• Phase III Study of AK112 for NSCLC PatientsActive, not recruitingNCT06396065Phase 3
• A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)WithdrawnNCT06395090Phase 1/2
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT06390059Phase 2
• Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerTerminatedNCT06388369Phase 1/2
• Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDerWithdrawnNCT06385548Phase 1/2
• Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)WithdrawnNCT06384820Phase 2
• Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct AdenocarcinomaStatus unknownNCT06383533Phase 2
• Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT06381154Phase 2
• Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic CancerCompletedNCT06378047Phase 1
• Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaWithdrawnNCT06370871Phase 3
• Niraparib and Dostarlimab for Patients with MMR-D/MSI-H Colorectal CancersWithdrawnNCT06365970Phase 2
• Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaWithdrawnNCT06365619Phase 2
• Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2
• ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT06357858Phase 1
• Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical TrialActive, not recruitingNCT06356597Phase 2
• A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT06348199Phase 3
• A Study of MHB039A for Advanced Solid TumorActive, not recruitingNCT06345482Phase 1/2
• A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid TumorsActive, not recruitingNCT06341114Phase 1/2
• Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)WithdrawnNCT06337162Phase 1
• Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal CancerCompletedNCT06333769Phase 2
• A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)WithdrawnNCT06331598Phase 2
• Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaWithdrawnNCT06328036Phase 2
• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedNCT06325683Phase 2
• Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)Active, not recruitingNCT06322108Phase 2
• BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial CancerTerminatedNCT06321068Phase 2/3
• Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaCompletedNCT06320353Phase 3
• Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.TerminatedNCT06320080Phase 1
• Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingNCT06318286Phase 2
• A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerActive, not recruitingNCT06317311Phase 2
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC PatientsActive, not recruitingNCT06313970Phase 2
• A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerActive, not recruitingNCT06311721Phase 3
• Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1
• TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.TerminatedNCT06297642Phase 1
• A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)TerminatedNCT06295809Phase 2/3
• Toripalimab Combined With SBRT for NSCLCActive, not recruitingNCT06293690Phase 2
• PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCLWithdrawnNCT06290622Phase 1
• A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Active, not recruitingNCT06284564Phase 2
• A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLCTerminatedNCT06280196Phase 3
• Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaActive, not recruitingNCT06279403Phase 2
• A Study of BND-35 in Participants With Advanced Solid TumorsTerminatedNCT06274437Phase 1
• A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyActive, not recruitingNCT06268613Phase 1

← Immune Checkpoint Inhibitors overview